Immunohistochemical Study of Estrogen and Progesterone Receptor Expression in Endometrial Carcinoma

Abstract

BACKGROUND: Endometrial cancer is the fourth most common cancer affecting the women both from the point of view of incidence as well as mortality. ER/PR positivity helps to determine the need for hormonal treatment for endometrial cancer. METERIAL AND METHOD It is a reterospective study on 22 histopathologically proven cases of endometrial carcinoma between the age group 30 to 80 yr from 1 Jan 2021 to 30 June 2022. Those cases with inadequate sample or with history of pregnancy were excluded from study. ER and PR expression was seen with Immunohistochemistry kit protocol. RESULTS: Mean age of patients was 57.77 yrs. Endometrial carcinoma is more common in postmenopausal females. Bleeding per vaginum is the chief complaint. Most of the cases were well differentiated and of low grade.ER expression is positive in (15/17 88.2% )of cases of low grade /well differentiated , (4/4,100%) in moderately differentiated and not seen in high grade/ poorly differentiated endometrial carcinoma .PR expression seen in low grade/well differentiated is (14/17,82.4%) , in moderately differentiated is( 4/4,100%) and in high grade /poorly differentiated is (1/1, 100%)and not seen in high grade or poorly differentiated endometrial carcinoma .As the tumor invades deep in the myometrium ER and PR expression decreases. CONCLUSION: ER and PR are important prognostic biomarkers to predict response to anti hormonal therapy.